COMPARE · Reviewed July 2, 2026
CVSA vs LRN
Verdict: Side-by-side breakdown using the Bull Rankings model. CVSA scored 81.4, LRN scored 89.3 — LRN ahead by 7.8999999999999915.
CVSA
Covista Inc.
81.4
$129.88
Score gap
7.8999999999999915
LRN leads
LRN
Stride, Inc.
89.3
$90.44
The companies
CVSACovista Inc.
Why now
Education & Training Services · market cap $4.4b. 17% off the 52-week high of $156.26. Revenue growing +13%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $156.25 (implying +20% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 144% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
LRNStride, Inc.
Why now
Education & Training Services · market cap $3.8b. Down 47% from 52-week high of $171.17 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.50 — paying under fair value for the growth rate.
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 134% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Base grades (each contributes ~14.3% of base composite)
| CVSA | Component | LRN |
|---|---|---|
| C65 | FCF | C65 |
| B+85 | Rev | B+85 |
| B+85 | D/E | A-90 |
| B80 | P/E or P/S | A-90 |
| B+85 | PEG | A95 |
| Supplemental signals · feed the score, not on the row card | ||
| A-90 | FCF Yield | A95 |
| B+85 | ROE | B+85 |
| 82.5 | Base composite | 87.2 |
Adjustments (signed deltas applied on top of base)
CVSA
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
DCF cross-check (avg upside 92%)+1
Total+6
LRN
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
DCF cross-check (avg upside 74%)+1
Total+6
DCF cross-check (per-share value vs. live price)
| CVSA upside | Horizon | LRN upside |
|---|---|---|
| +70% | 1Y | +64% |
| +88% | 5Y | +73% |
| +117% | 10Y | +85% |
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.